MedTrace Logo

Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

NCT04470544 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-11-12

Study results available
· View outcomes & findings →

Summary

To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.

Conditions

  • Severe Acute Respiratory Syndrome

Interventions

DRUG

Camostat Mesilate

Given PO

OTHER

Standard of Care

At Investigator discretion

Sponsors & Collaborators

  • Alan Bryce

    lead OTHER

Principal Investigators

  • Alan H Bryce, M.D. · Academic and Community Cancer Research United

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-28
Primary Completion
2021-12-22
Completion
2022-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470544 on ClinicalTrials.gov